Construction of a circRNA - Mediated ceRNA Network Reveals Novel Biomarkers for Aortic Dissection

De-Bin Liu

Department of Cardiology, The Second People's Hospital of Shantou

You-Fu He

Department of Cardiology, Guizhou Provincial People's Hospital

Gui-Jian Chen

Department of Cardiology, The Second People's Hospital of Shantou

Hua Huang

Department of Cardiology, The Second People's Hospital of Shantou

Xu-Ling Xie

Department of Cardiology, The Second People's Hospital of Shantou

Wan-Jun Lin

Department of Cardiology, The Second People's Hospital of Shantou

Zhi-Jian Peng (✉ 983247770@qq.com)

Department of Cardiology, The Second People's Hospital of Shantou

---

Research Article

Keywords: circRNA, miRNA, mRNA, ceRNA, aortic dissection, bioinformatics analyses

Posted Date: November 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1059642/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at International Journal of General Medicine on April 1st, 2022. See the published version at <https://doi.org/10.2147/IJGM.S355906>.

Abstract

Background

Aortic dissection (AD) is a rare and lethal disorder with its genetic basis remains largely unknown. Many studies have confirmed that circular RNAs (circRNAs) play important roles in various physiological and pathological processes. However, the roles of circRNAs in AD are still unclear and need further investigation. The present study aimed to elucidate the underlying molecular mechanisms of circRNAs regulation in aortic dissection based on the circRNA-miRNA-mRNA competing endogenous RNA (ceRNA) network.

Methods

Expression profiles of circRNAs (GSE97745), miRNAs (GSE92427), and mRNAs (GSE52093) were downloaded from Gene Expression Omnibus (GEO) databases, and the differentially expressed RNAs (DERNAs) were subsequently identified in AD by bioinformatics analysis. Further bioinformatics analyses, including circRNA-miRNA-mRNA ceRNA network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, were used to predict the potential functions of circRNA-associated ceRNA regulatory network. RNA was isolated from human arterial blood samples after which quantitative real-time PCR (qRT-PCR) was performed to confirm the DERNAs.

Results

We identified 14 (5 up-regulated and 9 down-regulated) differentially expressed circRNAs (DEcircRNAs), 17 (8 up-regulated and 9 down-regulated) differentially expressed miRNAs (DEmiRNAs) and 527 (297 up-regulated and 230 down-regulated) differentially expressed mRNAs (DEmRNAs) when AD samples were compared with normal ascending aorta samples (adjusted P -value < 0.05 and $|\log_2FC| > 1.0$). KEGG pathway analysis indicated that DEmRNAs were related to focal adhesion and extracellular matrix (ECM) receptor interaction signaling pathways. Simultaneously, the present study successfully constructed a ceRNA regulatory network based on 1 circRNAs (hsa_circRNA_082317), 1 miRNAs (hsa-miR-149-3p) and 10 mRNAs (MLEC, ENTPD7, SLC16A3, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1) in AD. Furthermore, qRT-PCR demonstrated that hsa_circRNA_082317 and α_5 integrin (ITGA5) were significantly up-regulated in AD ($n = 3$), and hsa-miR-149-3p was dramatically down-regulated in AD ($n = 3$). The expression of hsa-miR-149-3p target mRNA, ITGA5, was positively modulated by hsa_circRNA_082317.

Conclusion

This is the first study to demonstrate the circRNA-associated ceRNA regulatory network is altered in AD, implying that circRNAs may play important roles in regulating the onset and progression of AD and thus may serve as potential biomarkers for the diagnosis and treatment of AD.

Introduction

Aortic dissection (AD) is a rare but often fatal condition [1]. The separation of the aortic intima causes blood to leak into the space between the intima and the media, forming intramural hematoma and the true and false lumen along

the artery's long axis. To investigate patients with suspected aortic dissection, computed tomography angiography (CTA) is currently the international and widely accepted gold standard [2]. Increased C-reactive protein (CRP) and D-dimer levels, which are nonspecific markers of systemic inflammation, have been linked to acute aortic dissection (AAD) [3, 4]. There is currently no effective serum diagnostic or therapeutic marker for AD. As a result, new potential biomarkers for the diagnosis and prognosis of AD must be discovered as soon as possible.

At the RNA level, previous studies have revealed molecular changes in various aortic diseases [5]. A new mechanism of the interaction of RNAs, known as the competing endogenous RNA (ceRNA) network, has received much attention in recent years. The hypothesis holds that miRNA is the core element in the ceRNA network, while transcripts such as circRNAs, lncRNAs, mRNAs, and other RNAs can act as miRNA sponges to competitively combine with the same miRNA response elements (MREs), and then represses the inhibition of miRNA on their target genes, whether in pathological or physiological situations [6]. Previously, several miRNAs have been confirmed to be closely involved in cardiovascular diseases and even maybe a new strategy for the diagnosis, therapy, or prediction in cardiovascular diseases. Certain miRNAs, such as miRNA-21 [7], miRNA-134-5p [8], miRNA-145 [9], miRNA-146b [10], have been reported to play definite roles in the development of AD.

Unlike miRNAs, circRNAs have high stability and tissue specificity, which form a continuous cycle of covalent closures without 5' or 3' polyadenylated tail, and are resistant to RNase R degradation or RNA exonuclease digestion. Recent evidence indicate that circRNAs are involved in various human diseases, such as cancer [11], Alzheimer's disease [12], and cardiovascular diseases [13, 14]. However, no research has shown that circRNAs and related ceRNA networks can be used as diagnostic or prognostic markers in AD.

In this study, we first identified the DEmRNAs, DEmiRNAs, and DEcircRNAs and constructed a reliable circRNA-associated ceRNA regulatory network in AD based on GEO datasets using bioinformatics analysis. Finally, we identified novel circRNA-associated ceRNAs modules of AD and provided new evidence for the early diagnostic and prognostic for AD patients.

Materials And Methods

1. Data Collection.

Gene Expression Omnibus (GEO) databases of the National Center for Biotechnology Information (NCBI) (<https://www.ncbi.nlm.nih.gov/geo/>) [15] is an international public repository for high throughput microarray and sequence-based data. Three datasets (GSE52093, GSE92427, GSE97745) for AD were retrieved and downloaded from GEO databases. The mRNAs datasets GSE52093 contained Stanford type A AD (n=7) and normal aortic tissue (n=5), and the samples were tested by the GPL10558 Illumina HumanHT-12 V4.0 expression bead chip platform. GSE92427 miRNAs profiles, including AAD (n=8), healthy (n=8) and aortic aneurysm (n=8) subjects, was analyzed with the GPL16770 platform [Agilent-031181 Unrestricted_Human_miRNA_V16.0_Microarray (miRBase release 16.0 miRNA ID version)]. The circRNAs microarray GSE97745 included 3 human TAD tissues and 3 age-matched normal donors tissues; the platform used for the microarray was GPL21825 074301 Arraystar Human CircRNA microarray V2.

2. Identification of DEcircRNAs, DEmiRNAs, and DEmRNAs.

Limma [16], a Bioconductor package in R software, was applied to screen DEmRNAs, DEmiRNAs, and DEcircRNAs with thresholds of adjusted P -value < 0.05 and $|\log_2FC| > 1.0$. Then volcano plot and heat map of the DERNAs were constructed using the R software.

3. Gene Ontology (GO) and pathway enrichment analysis of DEGs.

The GO [17], including biological processes (BP), cellular components (CC), and molecular functions (MF), and KEGG [18] enrichment analysis and visualization of DEmRNAs were performed by the R-packages 'clusterProfiler' [19], 'org.Hs.eg.db', 'enrichplot', 'ggplot2' with thresholds of P -value < 0.05 and q -value < 0.05 .

4. Construction of miRNA-mRNA pairs.

In our study, we used miRNA IDs from miRBase (<http://www.mirbase.org/>) [20] as the unified gene IDs. Target genes of DEmiRNAs were predicted by the Predictive Target Module of the miRWalk3.0 (<http://mirwalk.umm.uni-heidelberg.de/>) [21], including miRDB [22], miRTarBase [23], and TargetScan databases. Any genes with at least one database were counted as target genes of DEmiRNAs. Then the intersection of DEmiRNAs predicted target genes and DEmRNAs were identified by the online Venn diagram tool (Evenn, <http://www.ehbio.com/test/venn/#/>) [24] and the overlapped genes were used to construct the miRNA-mRNA regulatory network using the Cytoscape software (Version 3.7.2, <https://cytoscape.org/>) [25].

5. Construction of circRNA-miRNA pairs.

circBase (<http://www.circbase.org/>) [26] is a database that merged and unified datasets of circRNAs. We unified the circRNAs IDs based on circBase and collected the detailed information of the circRNA ID, gene symbol, and genome location. To analyze the functional effects of DEcircRNAs and predict which circRNA acts as a miRNA sponge, we used a Cancer-specific circRNA database (CSCD, <https://gb.whu.edu.cn/CSCD/>) [27] to predict the target relationship, through predicting the RNA binding protein (RBP) sites and MREs.

6. Reconstruction of the circRNA-miRNA-mRNA network.

Based on the identified DEmiRNA-DEmRNA and DEcircRNA-DEmiRNA relationship pairs, we screened the DEcircRNA-miRNA-mRNA interaction networks that linked by the shared miRNAs predicted as downstream targets of DEcircRNAs and upstream regulators of DEmRNAs. Then, the DEcircRNA-miRNA-mRNA interaction networks were visualized by using Cytoscape software (Version 3.7.2, <https://cytoscape.org/>).

7. Patients and Tissue Specimens

The study was conducted following the Declaration of Helsinki, and the protocol was approved by the Second People's Hospital of Shantou. Informed, written consent was obtained from all participants. Arterial blood specimens were collected from three type B aortic dissection patients undergoing stent graft at the hospital in 2021. Arterial blood samples were obtained from three age- and gender-matched healthy control undergoing coronary

angiographic. After collection, plasma specimens were frozen by immersion in liquid nitrogen and stored in an ultralow temperature freezer at -80°C until use (DW-86L388A, Haier).

8. RNA Extraction and qRT-PCR

Total RNA was extracted from human arterial blood samples (three samples from AD and healthy, respectively) using Trizol total RNA isolation reagent (Invitrogen, 93289), according to the manufacturer's instructions. For circRNA qRT-PCR analysis, DEcircRNAs, targeted DEmiRNAs, were selected for further investigation. Briefly, total RNA from each sample was digested with RNase R (Epicentre, Inc.) to remove linear RNAs and enrich the circRNAs. The differential expression of DEcircRNAs was confirmed through qRT-PCR (in triplicate) using the SYBR green PCR mix (Takara, RR820B) according to the manufacturer's instructions. The sequence of circRNA results was obtained from the database "circBase" (<http://www.circbase.org>). For miRNA and mRNA analysis, total RNA was reverse-transcribed using random hexamer primers. GAPDH was employed as the loading control for mRNA and circRNA, and U6 RNA was amplified as the loading control for miRNAs. Finally, the relative expression of circRNAs, miRNAs, and mRNAs were analyzed and quantified by the comparative quantitative cycle(Cq) ($2^{-\Delta\Delta\text{Cq}}$) method. All the primers were designed and synthesized by Sangon Biotech (Sangon Biotech, Shanghai, China), and the primers sequences are listed Table 6.

9. Statistics

All data were analyzed using SPSS17.0 statistics software. The significance was assessed by paired Student's t-test as appropriate (for the comparison of two groups) and $P < 0.05$ was considered statistically significant.

Results

1. Identification of differential expressed circRNAs, miRNAs and mRNAs.

The flowchart of the study is shown below (Figure 1). In this study, we obtained three microarray datasets (GSE97745 circRNAs microarray, GSE 92427 miRNAs profiles, GSE52093 mRNAs datasets) for AD from the online databases GEO, and the fundamental information of the datasets were summarized below (Table 1). Differential expression analysis was performed using the Limma R package, with the criteria of adjusted P -value < 0.05 and $|\log_2\text{FC}| > 1.0$. Based on the cut-off criteria, a total of 527 DEmRNAs (297 up-regulated and 230 down-regulated), 17 DEmiRNAs (8 up-regulated and 9 down-regulated), and 14 DEcircRNAs (5 up-regulated and 9 down-regulated) were identified when AD samples were compared with normal ascending aorta samples (Figure 2 A-F).

2. GO and KEGG pathway annotation of DEmRNAs.

To further investigate the corresponding biological functions of the DEmRNAs, GO and KEGG enrichment analyses were carried out using R packages 'clusterProfiler' and 'org.Hs.eg.db'. The GO enrichment analysis for DEmRNAs was divided into three main categories: BP, CC, and MF. GO enrichment analysis of DEmRNAs revealed that a total of 195, 43, and 6 GO terms were enriched in the BP, CC, and MF, respectively ($p < 0.05$) (Figure 3A, Table 2). For biological processes, GO terms were mainly associated with Chromosome segregation (GO:0007059), nuclear chromosome

segregation (GO:0098813), mitotic sister chromatid segregation (GO:0000070), muscle system process (GO:0003012), and regulation of mitotic sister chromatid separation (GO:0010965). For cellular components, GO terms were mainly included I band (GO:0031674), Z disc (GO:0030018), sarcomere (GO:0030017), myofibril (GO:0030016), and contractile fiber (contractile fiber). For molecular function, GO terms mainly involved calmodulin binding (GO:0005516), actin-binding (GO:0003779), structural constituent of muscle (GO:0008307), frizzled binding (GO:0005109), and histone kinase activity (GO:0035173). KEGG pathway analysis of the DEmRNAs revealed that 9 pathways were significantly enriched, of which the top 5 were Cell cycle (KEGG Pathway hsa04110), Oocyte meiosis (KEGG Pathway hsa04114), DNA replication (KEGG Pathway hsa03030), Focal adhesion (KEGG Pathway hsa04510) and Hypertrophic cardiomyopathy (KEGG Pathway hsa05410) (Figure 3B, Table 3).

3. Construction of miRNA-mRNA pairs.

To further identify potentially relevant miRNA-mRNA target interactions in AD progression, the miRWalk3.0 online database (<http://mirwalk.umm.uni-heidelberg.de/>) was utilized to predict the target genes of DEmiRNAs. 2933 genes were obtained and predicted as target genes of DEmiRNAs. These target genes and the DEmRNAs were compared, and 82 differentially expressed target genes were finally obtained (Figure 4A). Only the inversely correlated miRNA-mRNA pairs, including up-regulated miRNA-down-regulated mRNA pairs and down-regulated miRNA-up-regulated mRNA pairs, were considered a potential miRNA-mRNA interaction. After filtering, there were 62 mRNA has an opposite interaction with DEmiRNAs. Cytoscape 3.7.2. the software was used to construct and analyze miRNA-mRNA regulatory network based on the identified 93 pairs of DEmiRNAs-DEmRNAs comprising 16 miRNAs (7 up-regulated and 9 down-regulated) and 62 DEmRNAs (43 up-regulated and 19 down-regulated) (Figure 4B, Table 4).

4. Construction of circRNA-miRNA pairs.

A total of 14 DEcircRNAs were annotated using the circBase database, of which 8 were known (3 up-regulated and 5 down-regulated) and 6 were novel (2 up-regulated and 4 down-regulated). Only the annotated DEcircRNAs in the circBase were used for further analysis (Table 5). Possible miRNA binding sites in DEcircRNAs were predicted using web tools Cancer-specific circRNA database (CSCD, <https://gb.whu.edu.cn/CSCD>) (Figure 5). After searching the CSCD database and comparing the DEmiRNAs-DEmRNAs pairs, we identified 1 circRNA-miRNA pair, resulting in finally the up-regulated hsa_circRNA_082317 adjusting its MREs: hsa-miR-149-3p (Figure 6A). Furthermore, we found that hsa_circRNA_082317 is generated by back splicing of ubiquitin-conjugating enzyme E2 (UBE2H) gene, which is located on the 7q32 chromosome, encodes a member of the E2 ubiquitin-conjugating enzyme family.

5. Reconstruction of the circRNA-miRNA-mRNA network.

Based on the above intersections, we constructed a circRNA-miRNA-mRNA ceRNA regulatory network and visualized it via the Cytoscape software (version 3.7.2). The network featured a total of 12 nodes (one circRNA, one miRNA, ten mRNAs), 1 circRNA-miRNA relationship pair, and 10 miRNA-mRNA relationship pairs (Figure 6B). Ultimately, we have identified one up-regulated DEcircRNA (hsa_circRNA_082317), 1 down-regulated DEmiRNA (hsa-miR-149-3p) and 10 up-regulated DEmRNAs (MLEC, ENTPD7, SLC16A3, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1). Based on the results of KEGG pathway analyses, our data showed that ITGA5 was significantly associated with the ECM-receptor interaction pathway and the focal adhesion pathway.

6. Validation of Candidates.

To verify the authenticity of the ceRNA regulatory pathway in AD, we collected blood plasma samples from 3 AD patients and 3 healthy donors for qRT-PCR. The results have shown significant differences ($P < 0.05$) in the relative expression of hsa_circRNA_082317, hsa-miR-149-3p, and ITGA5 between AD patients and healthy control subjects (Figure 7).

Discussion

AD is an aortic disease associated with rapid progression, high morbidity, and mortality. The annual incidence of aortic disease is about 0.03%. In AAD Stanford type A, mortality rates of up to 40-50% have been reported within the first 48 hours [28]. With the advancement of diagnosis and treatment, AAD remains a significant challenge for physicians today. CTA is a common method for diagnosing AD [29]. However, CTA has several disadvantages, including long detection time, inherent technical difficulties, and high costs.

Traditional plasma biomarkers like D-Dimer or CRP have certain value in the diagnosis of aortic disease [3, 4], but there is evidence of misdiagnoses and missed diagnoses. As a result, patients with AAD who are not diagnosed and treated promptly may have poor outcomes. Because of the severity of AD, finding novel and specific biomarkers for early diagnosis and treatment is critical.

Studying the molecular mechanisms of the occurrence and development of AD is a major focus of current research. In the present study, we performed an analysis of dysregulated circRNAs, miRNAs and mRNAs between patients with AD and healthy controls. To our knowledge, this present study is the first to identify the interaction networks between circRNAs-miRNAs-mRNAs in aortic tissues of AD patients. The microarray datasets revealed that 527 DEmRNAs (297 up-regulated and 230 down-regulated), 17 DEmiRNAs (8 up-regulated and 9 down-regulated), and 14 DEcircRNAs (5 up-regulated and 9 down-regulated) were identified when aortic dissection samples were compared with normal ascending aorta samples (adjusted P -value < 0.05 and $|\log_2FC| > 1.0$).

circRNA, as a novel endogenous RNA, has recently drawn extensive attention. Accumulating evidence has confirmed that circRNAs can act as “miRNA sponges” to repress the inhibition of miRNA on their target genes [30, 31]. Notably, to the best of our knowledge, the mechanism of the effect of circRNA on AD has not been investigated, even though previous studies have found that the differential expression of circRNAs between human AD tissues and normal control tissues was universal. Hence, we hypothesized that the dysregulation of ceRNA expression can affect AD pathogenicity and progression, and circRNA was selected as the entry point for studying the underlying mechanism of ceRNA.

In the present study, bioinformatics analyses have shown that up-regulated DEcircRNA (hsa_circRNA_082317) might compete with one key DEmiRNAs (hsa-miR-149-3p) to mediate target DEmRNA expression in AD. Based on the circBase database, we discovered that hsa_circRNA_082317 is formed from the ubiquitin conjugating enzyme E2 H (UBE2H) gene. In yeast and human placenta, UBE2H is a both structurally and functionally highly conserved, ubiquitin-dependent system protein [32, 33]. The UBE2H gene, which is located on the 7q32 chromosome, encodes a member of the E2 ubiquitin-conjugating enzyme family [34]. Furthermore, UBE2H expression is increased following the activation of tumor necrosis factor- α /nuclear factor kappa B (TNF- α /NF- κ B) signaling pathway in both human cardiac and skeletal muscles [35]. Although the expression of hsa_circRNA_082317 is greatly increased, it is not yet clear whether hsa_circRNA_082317 contributes to the ubiquitin-dependent system in AD. This hypothesis needs to be further explored.

Further systemic bioinformatics analyses including the GO and KEGG pathway analysis were used to predict the functions of DEmRNAs suggesting they may play an important role in regulating ECM-receptor interaction and focal adhesion. The ECM-receptor interaction, a micro-environmental pathway, that maintains cell and tissue homeostasis. ECM is an extremely complex and dynamic structure that provides mechanical support to cells and structural integrity to tissues. ECM and ECM receptors might play crucial roles in the aortic. As a kind of cell surface adhesion molecule, integrins interact with several signaling molecules and activate intracellular signaling pathways, such as the PI3K/AKT pathway. By connecting the actin cytoskeleton of the cells to the extracellular matrix, integrins can maintain cell morphology and regulate cell behavior, such as in cell adhesion, proliferation, differentiation, and migration[36]. Media degradation is a major histopathological feature of AD, which includes the degradation of the ECM (particularly elastic fibers and collagen) that is associated with the depletion of the smooth muscle cells (SMCs), consequently causing artery wall weakness and injury and, eventually, leading to the formation of AD [37, 38]. As a member of the integrin α chain family, ITGA5 might be involved in the pathogenesis of AD by regulating cell–ECM adhesion and modulating adhesion-initiated signal transduction pathways.

Conclusion

Taken together, the present study successfully constructed a circRNA-miRNA-mRNA ceRNA network based on 1 circRNAs (hsa_circRNA_082317), 1 miRNAs (hsa-miR-149-3p) and 10 mRNAs (MLEC, ENTPD7, SLC16A3, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1) in AD. Furthermore, significant up-regulation of hsa_circRNA_082317, ITGA5 and down-regulation of hsa-miR-149-3p were verified using qRT-PCR analysis. It was revealed that hsa_circRNA_082317 might compete with hsa-miR-149-3p to mediate target ITGA5, associated with the ECM-receptor interaction pathway and the focal adhesion pathway, in regulating the occurrence and development of AD. But the sample size is too small, hsa_circRNA_082317, hsa-miR-149-3p and the mRNAs (MLEC, ENTPD7, SLC16A3, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1) need further investigation to explore its potential to serve as diagnostic, prognostic, and therapeutic in AD.

Abbreviations

AD, aortic dissection; AAD, acute aortic dissection; circRNAs, circular RNAs; ceRNA, competing endogenous RNA; MREs, miRNA response elements; RBP, RNA binding protein; GEO, Gene Expression Omnibus; NCBI, National Center for Biotechnology Information; CSCD, Cancer-specific circRNA database; DERNAs, differentially expressed RNAs; DEcircRNAs, differentially expressed circRNAs; DEMiRNAs, differentially expressed miRNAs; DEmRNAs, differentially expressed mRNAs; GO, Gene Ontology; BP, biological processes; CC, cellular components; MF, molecular functions; KEGG, Kyoto Encyclopedia of Genes and Genomes; qRT-PCR, quantitative real-time PCR; ECM, extracellular matrix; ITGA5, α 5 integrin; UBE2H, ubiquitin conjugating enzyme E2 H; CTA, computed tomography angiography; CRP, C-reactive protein; TNF- α /NF- κ B, tumor necrosis factor-alpha/nuclear factor kappa B; SMCs, smooth muscle cells;

Declarations

Ethics approval and consent to participate

The study was approved by Ethics Committee of the Second People's Hospital of Shantou (protocol number: EC20210912(3)-P01). Informed consent forms were signed by all participants.

Consent for publication

Not applicable.

Availability of data

The datasets generated and analyzed during the current study are available in the Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>)

database (Accession Number: GSE97745, GSE92427, GSE52093) All the data are available from the corresponding author on reasonable request.

Competing interests

The authors declare that there have no conflicts of interest.

Funding

This work was supported by Guizhou Provincial Health Commission project number (gzwkj 2021-102), Guizhou Provincial Traditional Chinese Medicine Project Fund (QZYY-2021-001), Guizhou Provincial High-level innovative talent training plan (Qian Ke He Talent (2016) 4023), and Guizhou Provincial Technology platform and talent team planning project (Qian Ke He Platform Talent (2017) 5405).

Authors' contributions

DL and YH: Conception and design, GC and HH: Provision of study materials or patients, XX and WL: Collection and assembly of data, DL: Data analysis and interpretation, YH: investigation and validation, ZP: supervision. DL: manuscript writing. DL and YH: writing, review, and editing. All authors read and approved the final manuscript.

Acknowledgments

Not Applicable.

Authors' information

¹Department of Cardiology, The Second People's Hospital of Shantou, Shantou 515000, Guangdong Province, China

²Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 550000, Guizhou Province, P.R. China.

³Guizhou Provincial Cardiovascular Disease Clinical Medicine Research Center, 550000, Guizhou Province, China.

⁴Medical College, Guizhou University, Guiyang 550025, Guizhou Province, China.

[†] De-Bin Liu and You-Fu He contributed equally to this work.

References

1. LeMaire SA, Russell L. **Epidemiology of thoracic aortic dissection.** *Nature reviews Cardiology* 2011, **8**(2):103-113.
2. Yoo SM, Lee HY, White CS. **MDCT evaluation of acute aortic syndrome.** *Thoracic surgery clinics* 2010, **20**(1):149-165.

3. Wen D, Du X, Dong JZ, Zhou XL, Ma CS. **Value of D-dimer and C reactive protein in predicting inhospital death in acute aortic dissection.** *Heart* 2013, **99**(16):1192-1197.
4. Weber T, Hogler S, Auer J, Berent R, Lassnig E, Kvas E, Eber B. **D-dimer in acute aortic dissection.** *Chest* 2003, **123**(5):1375-1378.
5. Cheng M, Yang Y, Xin H, Li M, Zong T, He X, Yu T, Xin H. **Non-coding RNAs in aortic dissection: From biomarkers to therapeutic targets.** *Journal of cellular and molecular medicine* 2020, **24**(20):11622-11637.
6. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. **A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?** *Cell* 2011, **146**(3):353-358.
7. Huang X, Yue Z, Wu J, Chen J, Wang S, Wu J, Ren L, Zhang A, Deng P, Wang K *et al.* **MicroRNA-21 Knockout Exacerbates Angiotensin II-Induced Thoracic Aortic Aneurysm and Dissection in Mice With Abnormal Transforming Growth Factor-beta-SMAD3 Signaling.** *Arteriosclerosis, thrombosis, and vascular biology* 2018, **38**(5):1086-1101.
8. Wang Y, Dong CQ, Peng GY, Huang HY, Yu YS, Ji ZC, Shen ZY. **MicroRNA-134-5p Regulates Media Degeneration through Inhibiting VSMC Phenotypic Switch and Migration in Thoracic Aortic Dissection.** *Molecular therapy Nucleic acids* 2019, **16**:284-294.
9. Li T, Liu C, Liu L, Xia H, Xiao Y, Wang X, Wang Y. **Regulatory Mechanism of MicroRNA-145 in the Pathogenesis of Acute Aortic Dissection.** *Yonsei medical journal* 2019, **60**(4):352-359.
10. Li J, Zhou Q, He X, Cheng Y, Wang D. **Expression of miR-146b in peripheral blood serum and aortic tissues in patients with acute type Stanford A aortic dissection and its clinical significance.** *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences* 2017, **42**(10):1136-1142.
11. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X, Huang S. **Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis.** *Cell research* 2015, **25**(8):981-984.
12. Lukiw WJ. **Circular RNA (circRNA) in Alzheimer's disease (AD).** *Frontiers in genetics* 2013, **4**:307.
13. Jiang S, Guo C, Zhang W, Che W, Zhang J, Zhuang S, Wang Y, Zhang Y, Liu B. **The Integrative Regulatory Network of circRNA, microRNA, and mRNA in Atrial Fibrillation.** *Frontiers in genetics* 2019, **10**:526.
14. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. **Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk.** *PLoS genetics* 2010, **6**(12):e1001233.
15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M *et al.* **NCBI GEO: archive for functional genomics data sets-update.** *Nucleic acids research* 2013, **41**(Database issue):D991-995.
16. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. **limma powers differential expression analyses for RNA-sequencing and microarray studies.** *Nucleic acids research* 2015, **43**(7):e47.
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT *et al.* **Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.** *Nature genetics* 2000, **25**(1):25-29.
18. Kanehisa M, Goto S. **KEGG: kyoto encyclopedia of genes and genomes.** *Nucleic acids research* 2000, **28**(1):27-30.
19. Yu G, Wang LG, Han Y, He QY. **clusterProfiler: an R package for comparing biological themes among gene clusters.** *Omics : a journal of integrative biology* 2012, **16**(5):284-287.
20. Kozomara A, Birgaoanu M, Griffiths-Jones S. **miRBase: from microRNA sequences to function.** *Nucleic acids research* 2019, **47**(D1):D155-D162.

21. Dweep H, Sticht C, Pandey P, Gretz N. **miRWalk–database: prediction of possible miRNA binding sites by "walking" the genes of three genomes.** *Journal of biomedical informatics* 2011, **44**(5):839-847.
22. Chen Y, Wang X. **miRDB: an online database for prediction of functional microRNA targets.** *Nucleic acids research* 2020, **48**(D1):D127-D131.
23. Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y *et al.* **miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database.** *Nucleic acids research* 2020, **48**(D1):D148-D154.
24. Chen T, Zhang H, Liu Y, Liu YX, Huang L. **EVENN: Easy to create repeatable and editable Venn diagrams and Venn networks online.** *Journal of genetics and genomics = Yi chuan xue bao* 2021.
25. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. **Cytoscape: a software environment for integrated models of biomolecular interaction networks.** *Genome research* 2003, **13**(11):2498-2504.
26. Glazar P, Papavasileiou P, Rajewsky N. **circBase: a database for circular RNAs.** *Rna* 2014, **20**(11):1666-1670.
27. Xia S, Feng J, Chen K, Ma Y, Gong J, Cai F, Jin Y, Gao Y, Xia L, Chang H *et al.* **CSCD: a database for cancer-specific circular RNAs.** *Nucleic acids research* 2018, **46**(D1):D925-D929.
28. Levy D, Goyal A, Grigorova Y, Farci F, Le JK. **Aortic Dissection.** In: *StatPearls*. Treasure Island (FL); 2021.
29. Weber TF, Ganten MK, Bockler D, Geisbusch P, Kauczor HU, von Tengg-Kobligk H. **Heartbeat-related displacement of the thoracic aorta in patients with chronic aortic dissection type B: quantification by dynamic CTA.** *European journal of radiology* 2009, **72**(3):483-488.
30. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. **Natural RNA circles function as efficient microRNA sponges.** *Nature* 2013, **495**(7441):384-388.
31. Militello G, Weirick T, John D, Doring C, Dimmeler S, Uchida S. **Screening and validation of lncRNAs and circRNAs as miRNA sponges.** *Briefings in bioinformatics* 2017, **18**(5):780-788.
32. Qin S, Nakajima B, Nomura M, Arfin SM. **Cloning and characterization of a *Saccharomyces cerevisiae* gene encoding a new member of the ubiquitin-conjugating protein family.** *The Journal of biological chemistry* 1991, **266**(23):15549-15554.
33. Kaiser P, Mandl S, Schweiger M, Schneider R. **Characterization of functionally independent domains in the human ubiquitin conjugating enzyme Ubch2.** *FEBS letters* 1995, **377**(2):193-196.
34. Vourc'h P, Martin I, Bonnet-Brilhault F, Marouillat S, Barthelemy C, Pierre Muh J, Andres C. **Mutation screening and association study of the UBE2H gene on chromosome 7q32 in autistic disorder.** *Psychiatric genetics* 2003, **13**(4):221-225.
35. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. **TNF- α increases ubiquitin-conjugating activity in skeletal muscle by up-regulating Ubch2/E220k.** *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2003, **17**(9):1048-1057.
36. Hynes RO. **Integrins: bidirectional, allosteric signaling machines.** *Cell* 2002, **110**(6):673-687.
37. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q, Jahangiri M, Mayr M. **Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach.** *Molecular & cellular proteomics : MCP* 2011, **10**(8):M111 008128.
38. Wang L, Zhang J, Fu W, Guo D, Jiang J, Wang Y. **Association of smooth muscle cell phenotypes with extracellular matrix disorders in thoracic aortic dissection.** *Journal of vascular surgery* 2012, **56**(6):1698-1709, 1709 e1691.

Tables

Table 1. The fundamental information of the Three Microarray Datasets from GEO.

Data datasets	Series	Platform	Authors	Publication	Year	Sample size (T/N)
mRNAs	GSE52093	GPL10558	Pan S et al	-	2014	7/5
miRNAs	GSE92427	GPL16770	Dong J et al	Sci Rep.	2017	8/8
circRNAs	GSE97745	GPL21825	Zou M et al	Oncotarget	2020	3/3

Table 2. GO Analysis for DEmRNAs of GSE52093

Term	ID	Count	P-value	Genes
Chromosome segregation	GO:0007059	32	9.03E-13	ECT2, CDT1, ESPL1, ZWINT, CDC20, PTTG3P, RCC2, GEM, MAD2L2, CENPF, PTTG1, TRIP13, KIF14, CDCA5, OIP5, BIRC5, FEN1, MAD2L1, RACGAP1, TTK, CCNE1, CENPN, AURKB, UBE2C, CCNE2, CDCA2, KIF4A, NCAPG, CENPK, PSRC1, RMI1, BEX4
nuclear chromosome segregation	GO:0098813	27	2.26E-11	ECT2, CDT1, ESPL1, ZWINT, CDC20, PTTG3P, RCC2, GEM, MAD2L2, CENPF, PTTG1, TRIP13, KIF14, CDCA5, FEN1, MAD2L1, RACGAP1, TTK, CCNE1, AURKB, UBE2C, CCNE2, KIF4A, NCAPG, CENPK, PSRC1, RMI1
mitotic sister chromatid segregation	GO:0000070	20	2.31E-10	CDT1, ESPL1, ZWINT, CDC20, PTTG3P, MAD2L2, CENPF, PTTG1, TRIP13, KIF14, CDCA5, MAD2L1, RACGAP1, TTK, AURKB, UBE2C, KIF4A, NCAPG, CENPK, PSRC1
muscle system process	GO:0003012	33	4.86E-10	RYR2, PDLIM5, ACTC1, CNN1, SLMAP, ITGA2, SMTN, CASQ1, CAMK2G, MYOZ2, MYOM1, G6PD, ACTG2, GPD1L, PPP1R12B, CASQ2, SORBS1, DES, HMOX1, MYL9, RGS2, ADRA1B, EZH2, AKAP6, GSN, MYLK, MYOC, CALD1, MIR21, TPM1, SORBS2, SMPX, FGF12
regulation of mitotic sister chromatid separation	GO:0010965	13	5.75E-10	CDT1, ESPL1, ZWINT, CDC20, PTTG3P, MAD2L2, CENPF, PTTG1, TRIP13, MAD2L1, TTK, AURKB, UBE2C
negative regulation of sister chromatid segregation	GO:0033046	11	6.70E-10	CDT1, ZWINT, CDC20, PTTG3P, MAD2L2, CENPF, PTTG1, TRIP13, MAD2L1, TTK, AURKB
negative regulation of mitotic sister chromatid segregation	GO:0033048	11	6.70E-10	CDT1, ZWINT, CDC20, PTTG3P, MAD2L2, CENPF, PTTG1, TRIP13, MAD2L1, TTK, AURKB
negative regulation of mitotic sister chromatid separation	GO:2000816	11	6.70E-10	CDT1, ZWINT, CDC20, PTTG3P, MAD2L2, CENPF, PTTG1, TRIP13, MAD2L1, TTK, AURKB
mitotic nuclear division	GO:0140014	26	7.22E-10	CDT1, ESPL1, ZWINT, CDC20, CHEK1, PTTG3P, MAD2L2, PKMYT1, CENPF, PTTG1, TRIP13, KIF14, CDCA5, CCNB2, MAD2L1, RACGAP1, AURKA, TTK, AURKB, UBE2C, KIF4A, NCAPG, KIF11, CENPK, PSRC1, BTC
nuclear division	GO:0000280	32	7.47E-10	CDT1, ESPL1, ZWINT, CDC20, CHEK1, PTTG3P, MAD2L2, PKMYT1, CENPF, PTTG1, TRIP13, KIF14, CDCA5, CCNB2, MAD2L1, RACGAP1, AURKA, TTK, CCNE1, RAD54L, CKS2, RAD51AP1, AURKB, UBE2C, CCNE2, KIF4A, NCAPG, KIF11, CENPK, PSRC1, BTC, RMI1
I band	GO:0031674	19	4.19E-11	CFL2, RYR2, PDLIM5, ACTC1, FHOD3, CSRP1, CASQ1, NEXN, MYOZ2, LDB3, JPH2, PPP1R12B, CASQ2, FBXL22, DES, MYL9, PGM5, PPP1R12A, SORBS2
Z disc	GO:0030018	18	6.97E-11	CFL2, RYR2, PDLIM5, FHOD3, CSRP1, CASQ1, NEXN, MYOZ2, LDB3, JPH2, PPP1R12B, CASQ2, FBXL22, DES, MYL9, PGM5, PPP1R12A, SORBS2

sarcomere	GO:0030017	22	2.60E-10	CFL2, RYR2, PDLIM5, ACTC1, FHOD3, CSRP1, CASQ1, NEXN, MYOZ2, MYOM1, LDB3, JPH2, PPP1R12B, CASQ2, FBXL22, DES, MYL9, PGM5, PPP1R12A, TPM1, SORBS2, SMPX
myofibril	GO:0030016	23	3.00E-10	CFL2, RYR2, PDLIM5, ACTC1, FHOD3, CSRP1, CASQ1, NEXN, MYOZ2, MYOM1, LDB3, JPH2, PPP1R12B, CASQ2, FBXL22, DES, MYL9, PGM5, PPP1R12A, CALD1, TPM1, SORBS2, SMPX
contractile fiber	contractile fiber	23	5.53E-10	CFL2, RYR2, PDLIM5, ACTC1, FHOD3, CSRP1, CASQ1, NEXN, MYOZ2, MYOM1, LDB3, JPH2, PPP1R12B, CASQ2, FBXL22, DES, MYL9, PGM5, PPP1R12A, CALD1, TPM1, SORBS2, SMPX
spindle	GO:0005819	28	7.65E-09	CDC7, ECT2, ESPL1, CDC20, TBL1X, RCC2, GEM, MAD2L2, CENPF, KIF20A, KIF14, FAM110A, BIRC5, ASPM, MAD2L1, RACGAP1, LATS2, CKAP2L, AURKA, TTK, PKD2, PLK4, AURKB, RANGAP1, KIF4A, KIF11, PSRC1, BEX4
chromosomal region	GO:0098687	26	1.59E-08	CDT1, ZWINT, CHEK1, RCC2, CENPF, MCM4, CDCA5, ZWILCH, OIP5, MCM2, BIRC5, FEN1, MAD2L1, TTK, CENPN, RAD51AP1, PPP1R12A, EZH2, AURKB, HELLS, PCNA, RANGAP1, RECQL4, CENPM, NCAPG, CENPK
chromosome, centromeric region	GO:0000775	18	1.46E-07	CDT1, ZWINT, RCC2, CENPF, CDCA5, ZWILCH, OIP5, BIRC5, MAD2L1, TTK, CENPN, PPP1R12A, AURKB, HELLS, RANGAP1, CENPM, NCAPG, CENPK
mitotic spindle	GO:0072686	15	9.72E-07	CDC7, ECT2, ESPL1, TBL1X, RCC2, GEM, ASPM, MAD2L1, RACGAP1, CKAP2L, AURKA, PKD2, AURKB, RANGAP1, KIF11
sarcoplasm	GO:0016528	10	5.21E-06	SLC2A4, RYR2, CASQ1, CAMK2G, JPH2, FABP3, CASQ2, MEF2C, AKAP6, GSN
calmodulin binding	GO:0005516	16	6.21E-06	RYR2, CNN1, GEM, CAMK2G, MAPKAPK3, MYO1F, ASPM, RGS2, PNCK, PCP4, UNC13C, MYLK, REM1, GAP43, CALD1, ITPKC
actin binding	GO:0003779	25	1.03E-05	CFL2, PDLIM5, CNN1, FHOD3, ACTN4, SMTN, NEXN, MYOZ2, KPTN, MYOM1, LDB3, FXYD5, ENC1, SYN1, MYO1F, SORBS1, COBLL1, STK38L, WASF3, GSN, MYLK, PKNOX2, DSTN, CALD1, TPM1
structural constituent of muscle	GO:0008307	7	2.83E-05	CSRP1, SMTN, NEXN, MYOM1, MYL9, TPM1, SORBS2
frizzled binding	GO:0005109	6	1.25E-04	BAMBI, FZD7, FZD1, SFRP1, MYOC, NDP
histone kinase activity	GO:0035173	4	3.11E-04	JAK2, CHEK1, AURKA, AURKB
protein serine, threonine kinase activity	GO:0004674	21	4.35E-04	CDC7, CHEK1, MELK, CAMK2G, PKMYT1, MAPKAPK3, BMPR1A, LIMK1, LATS2, AURKA, TTK, SRPK3, PNCK, CDK5, STK38L, PLK4, AURKB, MYLK, IRAK1, MAPK13, MARK1

Table 3. KEGG Pathways Analysis for DEmRNAs of GSE52093

Term	ID	Count	<i>P</i> value	Genes
Cell cycle	hsa04110	16	7.11E-08	CDC7, ESPL1, CDC20, CHEK1, MAD2L2, PKMYT1, PTTG1, MCM4, CCNB2, MCM2, MAD2L1, TTK, CCNE1, CCNE2, PCNA, CCNA2
Oocyte meiosis	hsa04114	13	2.00E-05	ESPL1, CDC20, MAD2L2, CAMK2G, PKMYT1, PTTG1, CCNB2, MAD2L1, AURKA, CCNE1, CPEB2, MAPK13, CCNE2
DNA replication	hsa03030	7	2.59E-05	MCM4, MCM2, FEN1, POLE2, PCNA, POLA2, RNASEH2A
Focal adhesion	hsa04510	15	1.57E-04	COL6A3, ITGA2, ACTN4, COL6A6, PIK3R2, SPP1, PPP1R12B, MYL9, LAMB1, PPP1R12A, MYLK, ITGA7, SHC1, TNC, ITGA5
Hypertrophic cardiomyopathy	hsa05410	9	4.10E-04	RYR2, ACTC1, ITGA2, DES, SGCG, SGCD, ITGA7, TPM1, ITGA5
p53 signaling pathway	hsa04115	8	4.63E-04	CHEK1, CD82, CCNB2, SESN3, SERPINE1, CCNE1, TP53I3, CCNE2
Dilated cardiomyopathy	hsa05414	9	6.62E-04	RYR2, ACTC1, ITGA2, DES, SGCG, SGCD, ITGA7, TPM1, ITGA5
Progesterone-mediated oocyte maturation	hsa04914	9	8.90E-04	MAD2L2, PKMYT1, PIK3R2, CCNB2, MAD2L1, AURKA, CPEB2, MAPK13, CCNA2
ECM-receptor interaction	hsa04512	8	1.60E-03	COL6A3, ITGA2, COL6A6, SPP1, LAMB1, ITGA7, TNC, ITGA5

Table 4. The Basic Characteristics of DEmiRNAs of GSE92427

miRNA	logFC	adj. <i>P</i> .Val	Gene count	Differentially expressed target genes
hsa-let-7i-5p	2.302847	3.19E-02	8	CRY2, PPP1R12B, SDK1, REEP1, CPEB2, PDLIM5, KCTD10, RNF115
hsa-miR-1246	2.224846	4.02E-02	1	SORBS2
hsa-miR-29a-3p	1.901775	3.89E-02	1	CASZ1
hsa-miR-15a-5p	1.873268	4.91E-02	7	CPEB2, MN1, PDLIM5, MYLK, THSD4, PCGF5, REEP1
hsa-miR-15b-5p	1.60325	3.88E-02	4	MYLK, BMPR1A, MN1, REEP1
hsa-miR-29c-3p	1.572092	4.58E-02	2	HIF3A, CASZ1
hsa-let-7d-3p	1.506227	9.51E-03	0	-
hsa-miR-486-3p	1.235439	4.79E-02	4	PDLIM5, KCNB1, MCAM, CASQ2
hsa-miR-584-5p	-1.01627	9.65E-03	3	SESN3, PI15, ANGPT2
hsa-miR-3198	-1.07725	4.35E-03	1	RCC2
hsa-miR-1281	-1.08875	7.54E-04	2	SLC16A10, PPIF
hsa-miR-874-3p	-1.25865	3.30E-02	4	PTGS1, EIF4E2, IRAK1, CENPF
hsa-miR-1825	-1.26784	4.62E-02	3	ZWILCH, TSPAN5, SERPINE1
hsa-miR-671-5p	-1.33143	9.14E-03	3	ZDHHC9, FOXM1, PKNX2
hsa-miR-149-3p	-1.71921	1.12E-02	10	MLEC, ENTPD7, SLC16A3, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1
hsa-miR-	-1.8401	2.02E-03	1	SEC14L2

663a				
hsa-miR-494-3p	-2.01406	2.22E-02	39	ENTPD7, CHEK1, CCNE1, MLEC, PTGS1, SRPRB, TARBP2, PRRX1, COL6A3, GGCT, EIF4E2, RCC2, PI15, ZDHHC9, SLC16A3, FOXM1, SLC16A10, SESN3, RACGAP1, PKN0X2, TTC39C, POLQ, PPIF, SLC7A8, TBC1D16, PAQR4, MAPK13, PIK3R2, ITGA5, SERPINA1, ZWILCH, TSPAN5, SERPINE1, HNRNPF, RANGAP1, LIMK1, TP53I3, HMGB3, CDH6

Table 5. The Primary Characteristics of the DEcircRNAs of GSE97745

circRNA	logFC	adj. <i>P</i> .Val	circBase ID	position	Gene Symbol	CSCD
hsa_circRNA_103110	1.39680	4.63E-02	hsa_circ_0004771	chr21:16386664-16415895	NRIP1	Done
hsa_circRNA_082317	1.24147	4.63E-02	hsa_circ_0082317	chr7:129519407-129520811	UBE2H	Done
hsa_circRNA_405040	1.17399	4.63E-02	None	-	-	-
hsa_circRNA_083789	1.10988	4.72E-02	hsa_circ_0083789	chr8:27995214-28019595	ELP3	Done
hsa_circRNA_402563	1.06653	4.63E-02	None	-	-	-
hsa_circRNA_406326	-1.13794	4.68E-02	None	-	-	-
hsa_circRNA_103108	-1.18962	4.63E-02	hsa_circ_0061265	chr21:15456270-15456465	AP001347.6	Done
hsa_circRNA_042103	-1.20673	4.63E-02	hsa_circ_0042103	chr17:12608444-12626325	MYOCD	Done
hsa_circRNA_105038	-1.35553	4.63E-02	hsa_circ_0091894	chrX:153581139-153581292	FLNA	Done
hsa_circRNA_406309	-1.36792	4.72E-02	None	-	-	-
hsa_circRNA_405324	-1.78265	4.63E-02	None	-	-	-
hsa_circRNA_030448	-1.84029	4.63E-02	hsa_circ_0030448	chr13:76301164-76415337	LMO7	Done
hsa_circRNA_402094	-1.99931	4.63E-02	None	-	-	-
hsa_circRNA_000102	-2.04162	4.63E-02	hsa_circ_0000102	chr1:109479800-109479932	CLCC1	None

Table 6 Primer Sequences

Gene Name	Forward Primer	Reverse Primer
hsa_circRNA_082317	TGGAAAGTTAGAGTGGACCTACCTGA	TTCATTAAGTCCTCCCAGGATCGTAAC
has-miR-149-3p	TGGAAAGTTAGAGTGGACCTACCTGA	TATGGTTGTTACGACTCCTTCAC
ITGA5	CATCTTGGCATGCGCTCCA	GTCTTGGTGAACTCGGCACT
GAPDH	CGGACCAATACGACCAAATCCG	AGCCACATCGCTCAGACACC
U6	GCGCGTCGTGAAGCGTTC	GTGCAGGGTCCGAGGT

Figures

Figure 1

Flowchart of the approach utilized in this study.

Figure 2

Identification of differentially expressed RNAs (DERNAs). (A-C) Heatmap showing the expression of DEmRNAs, DEmiRNAs and DEcircRNAs, respectively; Each row in the heatmap represents a gene and each column represents a sample. The color scale at the right of the heatmap represents the raw Z-score ranging from blue (low expression) to red (high expression). (D-F) Volcano plot of DEmRNAs, DEmiRNAs and DEcircRNAs, respectively; The red nodes represent up-regulated; the green nodes represent down-regulated.

Figure 3

Bioinformatics enrichment analysis including GO analysis and KEGG pathway analysis for differentially expressed mRNAs of GSE52093 datasets. (A) Bubble diagram of Gene Ontology (GO) analysis of differentially expressed mRNAs revealed the enriched biological processes, cell components, and molecular functions. (B) Bar chart of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of targeted genes revealed the enriched signaling pathways.

Figure 4

The Venn Diagrams and DEmiRNA-DEmRNA regulatory network. (A) Venn diagram showing overlap genes both in the differential expression miRNAs (DEmiRNAs) predicted target genes and DEmRNAs. The overlap areas represent differentially expressed target genes. (B) Visualization of the miRNA-mRNA network, which is composed of 16 miRNA nodes, 62 mRNA nodes, and 93 edges. The triangle nodes represent the mRNAs, and the diamond nodes represent the miRNAs. Red represents up-regulated expression, whereas green represents down-regulated expression.

Figure 5

The fundamental structure modes of the candidate circRNAs predicted by CSCD. (A) Up-regulated circRNAs: hsa_circRNA_103110, hsa_circRNA_082317, hsa_circRNA_083789.(B) Down-regulated circRNAs: hsa_circRNA_103108, hsa_circRNA_105038, hsa_circRNA_030448.

A

B

Figure 6

CircRNA-miRNA-mRNA interaction network. (A) Visualization of the circRNA-miRNA network, which is composed of 1 circRNA node, 1 miRNA node and 1 edge. (B) Visualization of the circRNA-miRNA-mRNA network, which is composed of 1 circRNA node, 1 miRNA node, 10 mRNA nodes, and 11 edges. Hexagon, Diamond, and Triangle nodes represent circRNAs, miRNAs, and mRNAs, respectively. Red represents up-regulated expression, whereas green represents down-regulated expression.

Figure 7

Validation of DERNAs expression. (A) Expression of hsa_circRNA_082317 between healthy donors aorta and aortic dissection; (B) Expression of hsa-miR-149-3p between healthy donors aorta and aortic dissection; (C) Expression of ITGA5 mRNA between healthy donors aorta and aortic dissection. Black represented healthy donors samples, and grey represented aortic dissection samples (n = 3 samples/group, * $p \leq 0.05$, ** $p \leq 0.01$, data are represented as mean $\pm$ SD).